Telomir Pharmaceuticals Inc (NASDAQ: TELO) has experienced a rise in its stock price by 8.44 compared to its previous closing price of 3.91. However, the company has seen a fall of -1.17% in its stock price over the last five trading days. accessnewswire.com reported 2025-02-21 that MIAMI, FLORIDA / ACCESS Newswire / February 21, 2025 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), or Telomir, a leader in age-reversal science, today announced a breakthrough achievement-Telomir-1 has successfully captured and stabilized both Silver(I) (Ag⁺) and the highly reactive Silver(II) (Ag²⁺) in a biologically compatible form. This milestone overcomes a major limitation in silver-based medical applications, opening the door for advanced antimicrobial treatments, wound care solutions, and infection-resistant medical coatings.
Is It Worth Investing in Telomir Pharmaceuticals Inc (NASDAQ: TELO) Right Now?
Moreover, the 36-month beta value for TELO is -1.22. Analysts have varying opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for TELO is 17.12M and currently, short sellers hold a 7.48% of that float. On February 25, 2025, TELO’s average trading volume was 196.44K shares.
TELO’s Market Performance
TELO stock saw a decrease of -1.17% in the past week, with a monthly decline of -10.74% and a quarterly a decrease of -4.50%. The volatility ratio for the week is 9.51%, and the volatility levels for the last 30 days are 7.81% for Telomir Pharmaceuticals Inc (TELO). The simple moving average for the past 20 days is -3.20% for TELO’s stock, with a -13.49% simple moving average for the past 200 days.
Analysts’ Opinion of TELO
Many brokerage firms have already submitted their reports for TELO stocks, with Rodman & Renshaw repeating the rating for TELO by listing it as a “Buy.” The predicted price for TELO in the upcoming period, according to Rodman & Renshaw is $15 based on the research report published on February 21, 2025 of the current year 2025.
TELO Trading at -7.73% from the 50-Day Moving Average
After a stumble in the market that brought TELO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -55.56% of loss for the given period.
Volatility was left at 7.81%, however, over the last 30 days, the volatility rate increased by 9.51%, as shares sank -15.71% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -26.90% lower at present.
During the last 5 trading sessions, TELO fell by -1.17%, which changed the moving average for the period of 200-days by -29.92% in comparison to the 20-day moving average, which settled at $4.38. In addition, Telomir Pharmaceuticals Inc saw 2.91% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for TELO
The total capital return value is set at -14.61. Equity return is now at value -813.12, with -544.22 for asset returns.
The liquidity ratio also appears to be rather interesting for investors as it stands at 1.94.
Conclusion
To wrap up, the performance of Telomir Pharmaceuticals Inc (TELO) has been bad in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
